Effects of kynurenine pathway metabolites on intracellular NAD+ synthesis and cell death in human primary astrocytes and neurons

International Journal of Tryptophan Research

Volumn 2, Issue 1, 2009, Pages 61-69

  Braidy, Nady ^a   Grant, Ross ^a,b   Brew, Bruce J ^c,d   Adams, Seray ^a   Jayasena, Tharusha ^a   Guillemin, Gilles J ^a,d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY ADVENTIST HOSPITAL   (Australia)

^c Lowy Packer Building   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67651228062     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/ijtr.s2318     Document Type: Article

References (63)

1. Grant RS, Passey R, Matanovic G, Smythe G, Kapoor V. Evidence for increased de-novo synthesis of NAD in immune-activated RAW264.7 macrophages: a self-protective mechanism? Arch Biochem Biophys. 1999;372:1-7.
2. + Anabolism: Therapeutic Potential for Oxidative Stress in Ageing and Alzheimer's Disease. Neurotox Res. 2008;13(3, 4):173-184.
3. Berger SJ, Sudar DC, Berger NA. Metabolic consequences of DNA damage: DNA damage induces alterations in glucose metabolism by activation of Poly(ADP-ribose) polymerase. Biochem Biophys Res Commun. 1986;134:227-232.
4. Berger F, Ramirez-Hernandez MH, Ziegler M. The new life of a centenarian: signalling functions of NADP. Trends Biochem Sci. 2004;29:111-118.
5. Lee HC. Physiologic functions of cyclic ADP-ribose and NAADP as calcium messengers. Ann Rev Pharmacol Toxicol. 2001;41:317-345.
6. + depletion. Cell Physiol Biochem. 2007;20:45-54
7. Ha HC, Snyder SH. Poly(ADP-ribose) polymerase-I in the nervous system. Neurobiol Dis. 2000;7:225-239.
8. Love S, Barber R, Wilcock GK. Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease. Brain. 1999;122:247-253.
9. Sauve AA, Wolberger C, Schramm VL, Boeke JD. The biochemistry of Sirtuins. Annu Rev Biochem. 2006;75:435-465.
10. Anderson RM, Bitterman KJ, Wood JG, et al. Manipulation of a nuclear NADP salvage pathway delays ageing without altering steady-state NADP levels. J Biol Chem. 2002;277:18881-18890.
11. Penberthy TW. Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease. Curr Drug Metab. 2007;8:245-266.
12. + and NADH in cellular functions and cell death. Front Biosci. 2006;11:3129-3148.
13. Schwarcz R. The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharm. 2004;4:12-17.
14. Heyes MP, Saito K, Crowley JS, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurologic disease. Brain. 1992;115:1249-1273.
15. Stone TW. Endogenous neurotoxins from tryptophan. Toxicon. 2001;39(1):61-73.
16. Guillemin GJ, Kerr SJ, Brew BJ. Involvement of quinolinic acid in AIDS dementia complex. Neurotox Res. 2005;7(1-2):103-23.
17. Heyes MP, Brew BJ, Martin A, et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol. 1991;29(2):202-9.
18. Mackay GM, Forrest CM, Stoy N, et al. Tryptophan metabolism and oxidative stress in patients with chronic brain injury. Eur J Neurol. 2006;13:30-42.
19. Ruddick JP, Evans AK, Nutt DJ, Lightman SL, Rook GA, Lowry CA. Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med. 2006;8:1-27.
20. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schawrcz R. The brain metabolite kynureninic acid inhibits alpha7-nicotinic recceptor activity and increases non-alpha7 nicotinic receptor expression. J Neurosci. 2001;21:7463-7473.
21. Perkins MN, Stone TW. An iontophoretic investigation of the actions of convulsant kynurenines and their interactions with endogenous excitant quinolinic acid. Brain Res. 1982;247:184-187.
22. + depletion in neuronal cells. Neurosci Res. 2007;57:454-461.
23. Melillo G, Bosco MC, Musso T, Varesio L. Immunobiology of picolinic acid. Adv Exp Med Biol. 1996;398:135-141.
24. Bosco MC, Rapisarda A, Reffo G, Massazza S, Pastorino S, Varesio L. Macrophage activating properties of the tryptophan catabolite picolinic acid. Adv Exp Med Biol. 2003;527:55-65.
25. Kalisch BE, Jhamandas K, Boegman RJ, Beninger RJ. Picolinic acid protects against quinolinic acid-induced depletion of NADPH diaphorase containing neurons in the rat striatum. Brain Res. 1994;668(1-2):1-8.
26. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia. 2005;49(1):15-23.
27. Guillemin GJ, Kerr SJ, Smythe GA, et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001;78:842-853.
28. Bernofsky C, Swan M. An improved cycling assay for nicotinamide adenine dinucleotide. Anal Biochem. 1973;53:452-458.
29. Grant RS, Kapoor V. Murine glial cells regenerate NAD, after peroxideinduced depletion, using either nicotinic acid, nicotinamide, or quinolinic acid as substrates. J Neurochem. 1998;70:1759-1763.
30. Koh JY, Choi DW. Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Methods. 1987;20:83-90.
31. Bradford MM. A rapid and sensitive method for quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem. 1976;53:452-458.
32. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumourinduced tolerance. J Clin Invest. 2007;177:1147-54.
33. Werner ER, Fuchs D, Hausen A, et al. Tryptophan degradation in patients infected by human immunodeficiency virus. Biol Chem Hoppe Seyler. 1988;369:337-340.
34. Forrest CM, Macaky GM, Oxford L, Stoy N, Stone TW, Darlington LG. Kynurenine pathway metabolism in patients with osteoporosis after 2 years of drug treatment. Clin Exp Pharmacol Physiol. 2006;33: 1078-1087.
35. Myint AM, Kim YM, Verkerk R, Scharpe S, Steinbuch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007;98:143-51.
36. Schrocksnadel K, Winkler C, Fuith LC, Fuchs D. Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett. 2005;223:323-329.
37. Shibata K, Motooka K, Murata K. The differences in growth and activity of the tryptophan-NAD pathway between Wistar and Sprague-Dawley strains of rats fed on tryptophan limited diet. J Nutr Sci Vitaminol (Tokyo). 1982;28:11-19.
38. Backhaus C, Rahman H, Scheffler S, Laatsch H, Hardeland R. NO scavenging by 3-hydroxyanthranilic acid and 3-hydroxykynurenine: N-nitrosation leads via oxadiazoles to o-quinone diazides. Nitric Oxide. 2008;19(3):237-44.
39. Sas K, Robotka H, Toldi J, Vecsei L. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci. 2007;257:221-239.
40. Stone TW, Forrest CM, Mackay GM, Stoy N, Darlington LG. Tryptophan, adenosine, neurodegeneration and neuroprotection. Metab Brain Dis. 2007;22(3-4):337-352.
41. Smith AJ, Stone TW, Smith RA. Neurotoxicity of tryptophan metabolites. CNS. 2007;35(5):1287-1289.
42. Heyes MP, Saito K, Devinsky O, Nadi NS. Kynurenine pathway metabolites in cerebrospinal fluid and serum in complex partial seizures. Epilepsia. 1994;35:251-257.
43. Goldstein LE, Leopold MC, Huang X, et al. 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. Biochemistry. 2000;39:7266-7275.
44. Vazquez S, Garner B, Sheil MM, Truscott RJ. Characterisation of the major autoxidation products of 3-hydroxykynurenine under physiological conditions. Free Radic Res. 2000;32:11-23.
45. Guidetti P, Schwarcz R. 3-hydroxykynurenine and quinolinate: pathological synergism in early Huntington's disease? Adv Exp Med Biol. 2003;527:137-45.
46. Blight AR, Cohen TI, Saito K, Heyes MP. Quinolinic acid accumulation and functional deficits following experimental spinal cord injury. Brain. 1995;118:735-752.
47. Schuck PF, Tonin A, da Costa Ferreira G, et al. Kynurenines impair energy metabolism in rat cerebral cortex. Cell Mol Neurobiol. 2007;27:147-60.
48. Guillemin GJ, Cullen KM, Lim CK, et al. Characterisation of the kynurenine pathway in human neurons. J Neurosci. 2007;27:1-9.
49. Guillemin GJ, Brew BJ. Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep. 2002;7(4):199-206.
50. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's Disease hippocampus. Neuropathol Appl Neurobiol. 2005;31:395-404.
51. Braidy N, Grant R, Adams S, Guillemin G. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. (submitted).
52. Cammer W. Apoptosis of oligodendrocytes in secondary cultures from neonatal rat brains. Neurosci Lett. 2002;327(2):123-7.
53. Guillemin GJ, Wang L, Brew BJ. Quinolinic acid selectively induces apoptosis of human astocytes: Potential role in AIDS dementia complex. J Neuroinflammation. 2005;2(16):1-6.
54. Bush AI. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging. 2002;23:1031-1038.
55. Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy states. IJTR 2. 2009
56. Medana IM, Day NP, Salahifar-Sabet H, Stocker R, Smythe G, Bwanaisa L, Njobvu A, Kayira K, Turner GD, Taylor TE, Hunt NH. Metabolites of the kynurenine pathway of tryptophan metabolism in the cerebrospinal fluid of Malawian children with malaria. J Infect Dis. 2003;188(6): 844-849.
57. Melillo G, Bosco MC, Musso T, Varesio L. Immunobiology of picolinic acid. Adv Exp Med Biol. 1996;398:135-141.
58. Moroni P, Russi G, Lombardi G, Beni M, Carl V. Presence of kynurenic acid in the mammalian brain. J Neurochem. 1988;51:177-180.
59. Wu HQ, Guidetti P, Goodman JH, Varasi M, Ceresoli-Borroni G, Speciale C, et al. Kynurenergic manipulations influence excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo. Neuroscience. 2000;97:243-252.
60. Poeggeler B, Rassoulpour A, Guidetti P, Wu HQ, Schwarcz R. Dopaminergic control of kynurenate levels and NMDA toxicity in the developing rat striatum. Dev Neurosci. 1998;20:146-153.
61. Moroni P. Tryptophan metabolism and brain function: focus on kynurenine and other indol metabolites. Eur J Pharmacol. 1999;375:87-100.
62. Medana IM, Hien TT, Day NP, et al. The clinical significance of cerebrospinal fluid levels of kynurenine pathway metabolites and lactate in severe malaria. J Biol Chem. 2002;269:8128-8133.
63. Heyes MP, Lackner A. Increased cerebrospinal fluid quinolinic acid, kynurenic acid and L-kynurenine in acute septicemia. J Neurochem. 1990;55:338-341.